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Abstract
Background: Subtelomeric imbalance is widely accepted as related to developmental delay/mental retardation (DD/
MR). Fine mapping of aberrations in gene-enriched subtelomeric regions provides essential clues for localizing critical 
regions, and provides a strategy for identifying new candidate genes. To date, no large-scale study has been conducted 
on subtelomeric aberrations in DD/MR patients in mainland China.
Methods: This study included 451 Chinese children with moderate to severe clinically unexplained DD/MR. The 
subtelomere-MLPA (multiplex ligation dependent probe amplification) and Affymetrix human SNP array 6.0 were used 
to determine the subtelomeric copy number variations. The exact size and the breakpoint of each identified aberration 
were well defined.
Results: The submicroscopic subtelomeric aberrations were identified in 23 patients, with a detection rate of 5.1%. 16 
patients had simple deletions, 2 had simple duplications and 5 with both deletions and duplications. The deletions 
involved 14 different subtelomeric regions (1p, 2p, 4p, 6p, 7p, 7q, 8p, 9p, 10p, 11q, 14q, 15q, 16p and 22q), and 
duplications involved 7 subtelomeric regions (3q, 4p, 6q, 7p, 8p, 12p and 22q). Of all the subtelomeric aberrations 
found in Chinese subjects, the most common was 4p16.3 deletion. The sizes of the deletions varied from 0.6 Mb to 12 
Mb, with 5-143 genes inside. Duplicated regions were 0.26 Mb to 11 Mb, with 6-202 genes inside. In this study, four 
deleted subtelomeric regions and one duplicated region were smaller than any other previously reported, specifically 
the deletions in 11q25, 8p23.3, 7q36.3, 14q32.33, and the duplication in 22q13. Candidate genes inside each region 
were proposed.
Conclusions: Submicroscopic subtelomeric aberrations were detected in 5.1% of Chinese children with clinically 
unexplained DD/MR. Four deleted subtelomeric regions and one duplicated region found in this study were smaller 
than any previously reported, which will be helpful for further defining the candidate dosage sensitive gene associated 
with DD/MR.
Background
Developmental delay/mental retardation (DD/MR)
occurs in 1%-3% of the general population [1,2]. MR is
defined as a significant impairment of both cognitive (IQ
< 70) and social adaptive functions, with onset before 18
years of age. MR can not be diagnosed until the child is
older than 5 years, when the intelligence measurements
are reliable. For children younger than 5 years, the term
"DD" is usually used. The etiological diagnosis is chal-
lenging, because diverse genetic and environmental fac-
tors may contribute to its pathogenesis [3,4]. It is
estimated that 25%-50% of moderate to profound DD/
MR is resulted from genetic etiology [5]. G-banding kary-
otyping is a routine clinical test for DD/MR patients, and
the reported frequency with which it detects microscopic
chromosomal aberrations varies between 9%-36% [6].
However, microscopic techniques cannot detect intersti-
tial or terminal subtelomeric microdeletions and micro-
duplications [4]. Progress in molecular cytogenetic
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techniques, such as fluorescent in situ hybridization
(FISH), multiplex ligation dependent probe amplification
(MLPA) and array comparative genomic hybridization
(aCGH), has resulted in detection of submicroscopic sub-
telomeric rearrangements in approximately 5% (0-23%) of
DD/MR patients [7-14].
Subtelomeric regions are usually enriched for genes,
and are more susceptible to aberrant rearrangements
than other chromosomal regions [15,16]. Subtelomeric
imbalance is widely accepted as leading to DD/MR or
multiple congenital anomalies (MCA), although the exact
cause-and-effect relationship has not been well defined
[17-24]. The clinical consequences are probably deter-
mined by the location and kind of the rearrangement,
such as deletions or duplications, as well as the size of the
aberrations, including the numbers and function of the
genes involved [20]. These aberrant regions are likely to
contain undiscovered candidate genes associated with
DD/MR. Fine mapping of aberrant subtelomeric regions
to determine the critical regions and genes has become a
new strategy for identifying novel candidate genes for
DD/MR [25].
In 2007, 11,820,000 people in mainland China had an
intellectual disability, of whom 954,000 were younger
than 6 years of age. To date, no large-scale study has been
conducted on subtelomeric aberrations in Chinese DD/
MR patients. Here we report the investigation of 451 Chi-
nese children with clinically unexplained DD/MR, using
subtelomere-MLPA and Affymetrix human SNP array
6.0. Subtelomeric aberrations were identified, their exact
sizes were defined, and possible candidate genes are pro-
posed.
Methods
Patients
Patients with unexplained DD/MR were defined as those
without etiological diagnosis after thorough clinical eval-
uations, and were included based on the following crite-
ria: 1) moderate to severe DD/MR (IQ < 55, assessed with
Gesell Developmental Schedules or Wechsler intelligence
scale for children); 2) definite exclusion of perinatal brain
injury; 3) no history of toxication, hypoxia, central ner-
vous system infection and cranial trauma; 4) normal rou-
tine karyotyping; 5) no evidence of recognizable inherited
metabolic disorder or specific neurodegenerative disor-
ders by brain imaging and blood/urinary metabolic
screening; 6) negative for mutations in the FMR1 gene for
male patients; 7) negative for typical clinical features of
Rett syndrome for female patients.
All 451 subjects were Chinese children from the
Department of Pediatrics in Peking University First Hos-
pital and Department of Neurology in Beijing Children's
Hospital, recruited from 2006-2008, and informed con-
sent was obtained. Genomic DNA was extracted from
peripheral blood for each index patient and his or her
parents. T he research was approved by Medical E thics
Committee of Peking University First Hospital.
MLPA for screening of subtelomeric rearrangements
A specifically designed set of probes for testing subtelo-
meric imbalances in the SALSA P070 and P036B human
telomere test kits (MRC-Holland, Amsterdam, Nether-
lands; http://www.mrc-holland.com) was used. For each
patient with consistent positive results from both kits,
their parents' samples were tested.
The MLPA mix contained probes for all subtelomeric
regions except the short arms of the acrocentric chromo-
somes (13p, 14p, 15p, 21p and 22p), for which, probe rec-
ognition sequences were on the q arm, in one of the genes
just proximal to the telomeric repeats. Sequences
detected by two probes mixes were different from each
other. MLPA analysis was performed following the manu-
facturer's instruction. Amplification products were iden-
tified and quantified by capillary electrophoresis on an
ABI 3100 genetic analyzer. The fluorescent signal
strength of the PCR products was determined using
Genemarker1.5 software. For each patient, the normal-
ized peak pattern of each subtelomeric region was
divided by the average peak pattern of all samples (n > 10)
in the same experiment. The resulting values were
approximately 1.0 for wild type peaks, <0.75 for deletions,
and >1.3 for duplications.
Affymetrix human SNP array 6.0 assay
To confirm and accurately define the exact size of each
subtelomeric aberration region found by MLPA, Affyme-
trix genome-wide human SNP array 6.0 was used. Each
array has 1,800,000 genetic markers, including more than
906,600 single nucleotide polymorphisms (SNPs) and
more than 946,000 probes for the detecting copy number
variations (CNVs). The high density of the probes across
the genome and combination of a SNP array with aCGH
probes in a single chip enabled the accurate definition of
the size of each aberrant region.
Digestion, ligation, PCR, labeling, hybridization and
scanning were performed following standard protocols.
Partek software (version 6.3) was used for the analysis of
CNVs. Duplicated or deleted regions were determined by
Hidden Markov Model (HMM) calculation. Involvement
of at least three contiguous probe sets was required, and
when a copy number calculated by HMM as <1.5 was
considered a deletion, while >2.5 was considered a dupli-
cation.
Results
Screening of subtelomeric rearrangements with MLPA
revealed an abnormality in 34 of 451 patients. Deletion in
a single region was found in 22 patients (15pter del in 5;Wu et al. BMC Medical Genetics 2010, 11:72
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4pter del in 4; 13pter del in 3; 11qter del in 2; 9pter del in
2; and deletion in 1pter, 7qter, 8pter, 15qter, 16pter and
22qter in 1 patient each). Deletions in two different sub-
telomeric regions were identified in 2 patients (13pter del
+ 22qter del, 14qter del +17qter del). Duplication in sin-
gle subtelomeric region was found in 3 patients (3qter
dup in 2; 22qter dup in 1). 7 patients were found to have
both a deletion and duplication (8pter del + 7pter dup in
2; 2pter del + 4pter dup; 10pter del + 6qter dup; 9pter del
+ 19pter dup; 7pter del + 12pter dup; and 6pter del +
8pter dup). Subsequent MLPA assay for parents showed
that all rearrangements were absent in the parents.
To further confirm and accurately define the exact size
of each subtelomeric aberration detected by MLPA, sub-
sequent assay with Affymetrix genome-wide human SNP
array 6.0 was performed on 24 patients. Because the
MLPA probe recognition sequences for 13p and 15p are
actually on the q arm, and do not represent the subtelo-
meric regions, 8/34 subjects with 15pter del or 13pter del
were not studied further. Array analysis was also not per-
formed for an additional 2 of the 34, specifically with
8pter del + 7pter dup, and 9pter del + 19pter dup, due to
insufficiency of DNA samples.
Subtelomeric copy number aberrations were confirmed
in 23 of 24 patients, with a final detection rate of 5.1%
(23/451), of which 16 (69.6%) were found to have simple
deletions, 2 (8.7%) had a simple duplication and 5 (21.7%)
had complex rearrangements. The deletions involved 14
different subtelomeric regions (1p, 2p, 4p, 6p, 7p, 7q, 8p,
9p, 10p, 11q, 14q, 15q, 16p and 22q), and duplications
involved 7 subtelomeric regions (3q, 4p, 6q, 7p, 8p, 12p
and 22q). In 4p, 7p, 8p and 22q, both subtelomeric dele-
tions and duplications were detected. The size of the
deletions varied from 0.6 Mb to 12 Mb, with 5-143 genes
inside. Duplicated regions were 0.26 Mb to 11 Mb, with
6-202 genes inside.
Clinical features of patients and the results from MLPA
and Array are summarized in Table 1 and Table 2.
Discussion
Since the identification of submicroscopic subtelomeric
rearrangements as a cause of idiopathic MR in 1995, test-
ing for subtelomeric abnormalities has become an impor-
tant clinical evaluation step for the etiological diagnosis
of unexplained DD/MR in Western countries [1,4,26-29].
This is the first large-scale study carried out on submicro-
scopic subtelomeric aberrations in Chinese patients.
Subtelomeric aberrations identified in Chinese patients
Obtaining an accurate prevalence for subtelomeric aber-
rations in idiopathic DD/MR is difficult [7]. Using MLPA
followed by array analysis, we achieved a detection rate of
5.1% (23/451) in Chinese patients with moderate to
severe clinically unexplained DD/MR. This was compara-
ble to most previous reports on other populations. We
identified several well-known terminal deletion syn-
dromes in 4p16.3, 1p36, 22q13.3 and terminal 11q. Rare
chromosomal terminal aberrations were also found,
including deletions in 8p23.3, 7q36.3, 15q26.2-q26.3 and
14q32.3, as well as 22q13 duplication. Of all the subtelo-
meric aberrations found in Chinese subjects, the most
common was 4p16.3 deletion (Wolf-Hirschhorn syn-
drome), identified in 4/23. In this study, four deleted sub-
telomeric regions and one duplicated region were smaller
than any other previously reported, specifically the dele-
tions in 11q25, 8p23.3, 7q36.3, 14q32.33, and the duplica-
tion in 22q13. This information will be helpful for further
defining the critical regions that contain candidate DD/
MR- associated genes.
Subtelomeric aberrations smaller than previous reports
11q terminal deletion
We found 2 patients (patient 419 and 1591) with an 11q
terminal deletion, which is reported to present with DD,
short stature, congenital heart disease(CHD), thrombo-
cytopenia, genitourinary anomalies, pyloric stenosis, and
ophthalmologic defects. The critical regions of the dele-
tion might correlate with specific clinical phenotypes.
Grossfeld et al defined critical regions for 14 individual
phenotypes [30]. The smallest critical region (6.8 Mb)
they reported extended from D11S1351 (located in
11q24.2) to the telomere, and was associated with four
phenotypes, including Paris-Trousseau platelet disorder,
undescended testes, pyloric stenosis, and MR. Coldren et
al proposed two loci in distal 11q related to global and
selective deficits in neurocognitive function [31]. The
smallest deletion 11q terminus was reported by Berna-
ciakin in 2008, which was 5 Mb in size [32]. In our study,
patient 419 had a 4.11 Mb deletion in 11q25, spanning
from 130.33 Mb to 134.45 Mb (figure 1), which is smaller
than any other previous reports. The patient had DD and
facial dysmorphism including thin upper lip, V-shaped
mouth, micrognathia and low-set ears, but without plate-
let disorder, undescended testes or pyloric stenosis. Thus,
the critical region underlying the phenotype of DD/MR
in 11q terminal deletion disorder is probably in the most
distal part, within 4.11 Mb of the telomere. The deleted
region contains 20 genes, with 14 expressed in human
brain.  SNX19  (sorting nexin-19), THYN1  (thymocyte
nuclear protein 1), OPCML (opioid-binding protein/cell
adhesion molecule-like), VPS26B (vacuolar protein sort-
ing 26, yeast, homolog of B), NCAPD3 (non-SMC con-
densing II complex subunit D3) and NTM (neurotrimin)
might be candidate genes, and the encoded proteins are
associated with intracellular trafficking, phosphoinositide
binding, mitotic chromosome assembly and segregation,
outgrowth of neurites, and apoptosis.Wu et al. BMC Medical Genetics 2010, 11:72
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8p23.3 deletion
Microscopically visible distal 8p deletions are associated
with growth and mental impairment, minor facial anom-
alies, congenital heart defects, and behavioral problems.
Submicroscopic subtelomeric 8p deletion is uncommon,
wit h only a few report ed cases [33]. de V ries BB et al
reported two cousins with 5.1 Mb of terminal 8p deletion,
who presented with mild MR, normal facial appearance,
normocephaly and behavioral problems such as unsocial-
ized conduct disorder [34]. We found 1 patient (339) with
a very small deletion in terminal 8p, 2.06 Mb to the
telomere (in 8p23.3). This one-year-old girl presented
with DD, microcephaly and minor facial dysmorphism.
Thus, we can define the critical region underlying DD/
MR in subtelomeric 8p deletion within the distal 2.05 Mb.
This area contains 28 genes, and 12 are known to be
expressed in human brain. Among them, CLN8  and
DLGAP2 (discs large-associated protein 2) might be can-
didate genes. CLN8  is involved in lipid synthesis and
transportation, and mutations are related to neuronal
ceroid lipofuscinoses (NCL), an autosomal recessive neu-
rodegenerative disorder. The product of DLGAP2  is a
membrane-associated guanylate kinases localized at
postsynaptic densities in neuronal cells. This kinase is in
a family of signaling molecules found at various submem-
brane domains, and may play a role in the molecular
organization of synapses and in neuronal cell signaling.
7q terminal deletion
A few cases were found to have terminal 7q deletions.
The 7q36-qter deletion is usually associated with DD/
MR, low birth weight, growth retardation, abnormal skull
shape, and some facial dysmorphism like nose malforma-
tion, hypertelorism, and ear malformation [35]. This
study reports a patient with the smallest deletion (1.53
Mb) detected in terminal 7q to date. She was 2 years of
age, and presented with DD, microcephaly, low hair line,
ocular hypertelorism, ptosis, and prominent ear and hand
malformations. The deleted region was in 7q36.3, span-
ning from 157.29 Mb to 158.82 Mb, which contains only
seven genes. PTPRN2  (protein tyrosine phosphatase,
receptor type N), NCAPG2  (leucine zipper protein 5),
VIPR2  (vasoactive intestinal peptide receptor 2),
Table 1: The clinical characteristics of DD/MR patients with or without subtelomeric aberrations
Clinical Characteristics Patient with subtelomeric imbalance 
confirmed by MLPA and Array (23 patients)
N (%)
Patients without sub-telomeric aberrations 
(428 patients)
N (%)
Gender, M/F 10/13 300/128
Age 1.9 y (6 m-7 y 10 m) 4.2 y (4 m-29 y)
Seizure 3 (13.0) 117 (27.3)
Autistic features 0 (0.0) 0 (0.0)
Family history of DD/MR 3 (13.0) 64 (15.0)
Maternal history of miscarriages 3 (13.0) 9 (2.1)
Microcephaly 11 (47.8) 104 (24.3)
Macrocephaly 0 (0.0) 17 (4.0)
Low birth weight 7 (30.4) 32 (7.5)
Growth delay 5 (21.7) 104 (24.3)
Minor facial and non-facial 
dysmorphism
18(78.3) 217 (50.7)
Other congenital abnormalities 9 (39.1) 63 (14.7)W
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Table 2: Clinical findings, MLPA and Affymetrix SNP array 6.0 results in 24 patients underwent array assay
Patient
ID
MLPA Affymetrix human SNP 6.0 Array Clinical findings
Gain
/loss
Chromo-some 
band
Start 
(Mb)
End 
(Mb)
Size 
(Mb)
Number 
of genes
Gender Age Seizure Autistic 
feature
Dysmorphism or other 
congenital 
abnormalities
Micro-
cephaly
Low 
birth 
weight
Growth 
delay
Family 
history
1472 1pter- loss 1p36.33-p36.32 0.83 3.12 2.29 74 F 7 y 10 m / / hirsutism, hypertelorims, 
clinodactyly
/+ / /
1115 4pter- loss 4p16.3-p16.1 0.057 9.83 9.77 138 M 6 m / / Greek warrior helmet 
appearance of the nose, 
cleft lip/palate, 
polymicrogyria, thin 
corpus callosum
++ / /
1483 4pter- loss 4p16.3-p16.2 0.057 3.38 3.32 58 F 9 m / / Greek warrior helmet 
appearance of the nose, 
micrognathia, high-
arched palate,
dermatoglyphic 
anomalies
++ + /
1834 4pter- loss 4p16.3-p16.1 0.057 9.82 9.77 138 F 1 y 3 m + / Greek warrior helmet 
appearance of the nose, 
micrognathia, prominent 
ear, cleft palate, 
calcification of kidneys, 
hepatic hemangioma, 
CHD, dysplasia of atlas
++ + /
1980 4pter- loss 4p16.3-p16.2 0.056 4.12 4.07 67 F 1 y 2 m + / Greek warrior helmet 
appearance of the nose, 
high-arched palate, 
prominent ear
++ + +
1971 7qter- loss 7q36.3 157.29 158.82 1.53 7 F 2 y 1 m / / low hair line, 
hypertelorism, ptosis, 
prominent ears, hand 
anomalies
+/ / /W
u
 
e
t
 
a
l
.
 
B
M
C
 
M
e
d
i
c
a
l
 
G
e
n
e
t
i
c
s
 
2
0
1
0
,
 
1
1
:
7
2
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
3
5
0
/
1
1
/
7
2
P
a
g
e
 
6
 
o
f
 
1
2
339 8pter- loss 8p23.3 0.021 2.067 2.05 28 F 1 y / / hypertelorism, long 
philtrum, malformed ears
+/ / /
1467 9pter- loss 9p24.3 0.67 1.54 0.87 5 F 2 y 11 m / / / + / / /
2268 9pter- loss 9p24.3-24.1 0.19 7.01 6.82 48 M 3 y / / flat nasal bridge, 
prominent ears, 
dermatoglyphic 
anomalies
// / /
419 11qter- loss 11q25 130.33 134.45 4.12 20 M 7 m / / long philtrum, low set 
ears, micrognathia, thin 
upper lip, V-shaped 
mouth
/+ / /
1591 11qter - loss 11q23.3-q25 119.98 132.81 12.82 143 F 2 y 5 m / / light hair color, 
Hypertelorism, high-
arched palate, 
dermatoglyphic 
anomalies, CHD
// / /
1309 15qter- loss 15q26.2-q26.3 92.79 100.29 7.50 48 M 11 m / / flat nasal bridge, small 
palpebral fissure, 
hypertelorism, 
dermatoglyphic 
anomalies, clinodactyly, 
inguinal hernia, polycytic 
kidney
/+ / +
2689 16pter- loss 16p13.3 0.00077 1.28 1.28 69 F 6 y / / high-arched palate, 
hypertelorism, prominent 
ears, thin corpus callosum
// / /
2498 22qter- loss 22q13.32-13.33 47.43 49.41 1.97 41 F 3 y / / / / + / /
1038 3qter+ gain 3q29 194.37 199.38 5.01 67 M 5 y 10 m + / hirsutism, prominent ears, 
dermatoglyphic 
anomalies, CHD, 
cryptorchidism
+/ / /
Table 2: Clinical findings, MLPA and Affymetrix SNP array 6.0 results in 24 patients underwent array assay (Continued)W
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1518 3qter+ / / / / / / M 5 y 11 m + + hirsutism, prominent ears, 
sparse teeth
// / /
1729 22qter+ gain 22q13.33 49.32 49.58 0.26 7 F 7 m / / flat nasal bridge, small 
palpebral fissure, 
prominent ears, 
dermatoglyphic 
anomalies, CHD
+/ + /
1704 14qter- loss 14q32.33 104.53 105.21 0.68 24 M 4 y 6 m + / / / / / /
17qter- / / / / / /
390 13pter- / / / / / / M 1 y / / thin corpus callosum + / / /
22qter- loss 22q13.31-q13.33 46.90 49.58 2.68 46
337 2pter- loss 2p25.3 0.0028 2.02 2.01 19 F 8 m / / hypertelorism, flat nasal 
bridge
// / /
4pter+ gain 4p16.3 0.15 1.19 1.04 24
1947 10pter- loss 10p15.3-15.1 0.062 6.22 6.16 48 M 9 m / / hypertelorism, flat nasal 
bridge, micrognathia, 
CHD
+/ / +
6qter+ gain 6q27 165.60 166.43 0.82 6
1711 8pter- loss 8p23.3 0.16 1.91 1.75 17 M 4 y 10 m / / long philtrum + / / /
7pter+ gain 7p22.3 0.26 1.81 1.55 28
2126 6pter- loss 6p25.3 0.33 2.95 2.63 20 M 3 y 3 m / / thin corpus callosum / / / +
8pter+ gain 8p23.3 0.021 0.58 0.56 7
Table 2: Clinical findings, MLPA and Affymetrix SNP array 6.0 results in 24 patients underwent array assay (Continued)W
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2026 7pter- loss 7p22.3 0.26 2.01 1.76 23 F 1 y 7 m / / ptosis, long philtrum, 
downturned corners of 
the mouth
// / /
12pter+ gain 12p13.33-13.2 0.021 11.07 11.05 202
+ = positive, / = negative
Table 2: Clinical findings, MLPA and Affymetrix SNP array 6.0 results in 24 patients underwent array assay (Continued)Wu et al. BMC Medical Genetics 2010, 11:72
http://www.biomedcentral.com/1471-2350/11/72
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FAM62B  ( f a m i l y  w i t h  s e q u e n c e  s i m i l a r i t y  6 2 )  a n d
WDR60 (WD repeat domain 60) are expressed in human
brain. PTPRN2 and NCAPG2 might be candidates. The
protein encoded by PTPRN2 is a member of the protein
tyrosine phosphatase (PTP) family. PTPs are signaling
molecules that regulate a variety of cellular processes
including cell growth, differentiation, mitotic cycle, and
oncogenic transformation. NCAPG2 is a non-SMC
(structural maintenance of chromosome) subunit that
defines condensin II. Condensin complexes I and II play
essential roles in mitotic chromosome assembly and seg-
regation. It's reported that microcephalin/MCPH1 is one
of the causative genes responsible for the autosomal
recessive disorder primary microcephaly. Patients with
this disease present with mental retardation and dramatic
reduction in head size, and cells derived from these
patients contain abnormally condensed chromosomes.
More recently, MCPH1 has been implicated in the cellu-
lar response to DNA damage, although its exact mecha-
nism remains unclear. In 2008, Wood et al identified
condensin-II as a major MCPH1-interacting protein.
MCPH1 and condensin II interact in vivo, mediated by
the CAPG2 subunit of condensin II [36].
14q32.33 deletion
We identified one patient (1704) with a very small dele-
tion in 14q32.33. Terminal deletions of the 14q are rare.
T h e  c o m m o n  c l i n i c a l  f e a t u r e s  s h a r e d  b y  p a t i e n t s  w i t h
14qter deletions include mild to moderate DD/MR,
microcephaly, high forehead with lateral hypertrichosis,
broad nasal bridge, long and broad philtrum, thin upper
lip, high arched palate, single palmar crease, and hypoto-
nia [37]. Seizures are absent in most patients with 14qter
deletions, but were reported in one case with a 3.2 Mb
terminal deletion in 14q32.32 [38]. Early onset intractable
s e i z u r e s  u s u a l l y  p r e s e n t  i n  r i n g  1 4  r a t h e r  t h a n  1 4 q t e r
deletions [39]. Patient 1704, a 4-year-old boy, presented
with moderate DD and seizures, with no dysmorphism or
congenital abnormalities. The terminal 14q deletion
found in this patient is the smallest reported to date,
spanning from 104.53 Mb to 105.21 Mb, for only 0.68 Mb.
This region contains 24 genes, with 15 expressed in
human brain. MTA1  (metastasis associated protein),
BRF1  (transcription initiation factor IIIB isoform3),
NUDT14 (nucleoside diphosphate-linked moiety × motif
14) and JAG2 (jagged 2 isoform a precursor) might be
candidate genes for DD/MR. They are involved in regula-
tion of transcription, cell proliferation, glycosylation and
intercellular signal transduction.
22q13.3 deletion and duplication
We found both deletions and duplications in terminal 22q
(patient 390 with 22q13.31-13.33 deletion, patient 2498
with 22q13.32-13.33 deletion and patient 1729 with
22q13.33 duplication). 22q13.3 deletion syndrome is a
recognizable malformation syndrome associated with
DD, hypotonia, delayed or absent speech, autistic-like
behavior, normal to accelerated growth and dysmorphic
faces with epicanthal folds, large/dysplastic ears, pointed
chin, dolichocephaly and ptosis [40,41]. Anderlid et al
refined the critical area to 100 kb in 22q13.33, which con-
tains three genes, ProSAP2 (SHANK3), ACR (acrosin pre-
cursor) and RABL2B (RAB, member of RAS oncogene
family-like 2B) [42]. SHANK3 is a good candidate gene, as
it is preferentially expressed in the cerebral cortex and
cerebellum, and encodes a scaffolding protein involved in
the postsynaptic density of excitatory synapses. De novo
deletions and mutations of SHANK3 have been found in
individuals with autism [43-47]. The deleted region in
patient 390 was 2.68 Mb in size, extending from 4.69 Mb
to 4.96 Mb, containing 46 genes, including the reported
critical area. The patient had low birth weight, normal
growth and a thin corpus callosum. He was only one year
old, so delayed or absent speech or autistic behavior
could not be determined. With 1.97 Mb of deletion in
22q, patient 2498 showed absent speech at 3 years of age.
The 22q13 duplication is not common, with only a few
cases reported. Some clinical features, including intra-
Figure 1 Deletion in 11q25 shown in Affymetrix human SNP array 6.0. Affymetrix human SNP array 6.0 assay shows a 4.11 Mb deletion in 11q25, 
which is indicated with the dashed rectangle.Wu et al. BMC Medical Genetics 2010, 11:72
http://www.biomedcentral.com/1471-2350/11/72
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uterine growth retardation, CHD and other dysmor-
phism were described [48]. Patient 1729 had some facial
dysmorphism, CHD, microcephaly and growth delay. She
had a 258 kb duplication, spanning from 4.93 Mb to 4.96
Mb. To our knowledge, this is the smallest reported
duplication in the terminal region of 22q. Seven genes
reside in the duplicated area, which contains SHANK3,
ACR,  RABL2B,  MAPK8IP2  (mitogen-activated protein
kinase 8 interacting) and ARSA (arylsulfatase A, isoform
b). Therefore deletion as well as duplication of critical
genes like SHANK3, are likely to be associated with com-
mon phenotypes like DD/MR, since DD/MR is shared by
all patients with 22q13.33 deletion or duplication.
Subtelomeric duplications
We found pure terminal duplications in 2/451 subjects
(0.4%). Subtelomeric pure microduplications are an infre-
quent cause of MR/MCA with a frequency of approxi-
mately 0.5% [49]. We identified 22qter and 3qter
microduplications. Patient 1038 showed common fea-
tures of the dup (3q) syndrome including hirsutism,
microcephaly, low-set ears, malformation of hands, cryp-
torchidism and CHD [50]. He had recurrent afebrile sei-
zures since 3 months of age. A 5.0 Mb duplication in 3q29
(from 194.37 Mb to 199.38 Mb) was detected in this
patient, containing 67 genes. Our finding supports the
observation made by Battaglia et al. [51], who suggested
that the critical region underlying the phenotype of dup
3q is in 3q29.
Common phenotypes in submicroscopic subtelomeric 
aberrations
For most subtelomeric rearrangements, a specific pheno-
type has not been defined, making recognition and selec-
tion of patients for such tests challenging in clinical
practice. Some common clinical features might be shared
by patients with various subtelomeric abnormalities. A
five-item checklist of clinical features for pre-selection of
patients for subtelomeric rearrangements was proposed
by de Vries BB et al, including: 1) family history of MR; 2)
prenatal onset of growth retardation; 3) postnatal growth
abnormalities; 4) at least two facial dysmorphic features;
and 5) at least one non-facial dysmorphic feature and/or
congenital abnormality [52]. In our study, for patients
with moderate to severe DD/MR with a normal karyo-
type, those with subtelomeric rearrangements (n = 23)
had a higher percentage of microcephaly (47.8% vs.
24.3%), low birth weight (30.4% vs. 7.5%), maternal his-
tory of miscarriage (13.0% vs. 2.1%), facial/non-facial dys-
morphism (78.3% vs. 50.7%) and other congenital
abnormalities (39.1% vs. 14.7%), than those without sub-
telomeric rearrangement (table 1). Therefore, these might
b e  c o m m o n  f e a t u r e s  s h a r e d  b y  m o s t  D D / M R  p a t i e n t s
with submicroscopic subtelomeric aberrations. Nonethe-
less, some patients, like patient 1467, with an 874 kb dele-
tion in 9p24.3, only presented with DD and microcephaly.
And patient 1704, with a deletion in 14q32.33, had no
clinically recognizable dysmorphism.
Conclusions
This large-scale study reports the detection of submicro-
scopic subtelomeric aberrations in Chinese patients with
DD/MR for the first time. Subtelomeric rearrangements
were found in 5.1%. Although benign subtelomeric varia-
tions exist [53], most de novo subtelomeric aberrations
are considered pathogenic. Further observations of a
larger number of patients with similar submicroscopic
subtelomeric abnormalities may lead to the recognition
of specific phenotypes, and will be helpful in the clinical
etiologic diagnosis of DD/MR. More important, fine
mapping of aberrations in gene-enriched subtelomeric
regions provides essential clues for localizing critical
regions, and provides a strategy for identifying new can-
didate genes associated with DD/MR.
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